Skip to Main Content

Paper Details

Ruxolitinib reverses dysregulated T helper cell responses and controls autoimmunity caused by a novel signal transducer and activator of transcription 1 (STAT1) gain-of-function mutation.
J Allergy Clin Immunol
115
2017
-mutated patient cells, Autoimmunity, Janus kinase, Janus kinase 1/2, Naive lymphocytes, Ruxolitinib, STAT1, STAT1 GOF mutations, STAT1-mutated patient cells, T, T helper cell, TH1, TH17, TH17 cell, autoimmune cytopenias, autoimmunity, child, chronic mucocutaneous candidiasis, follicular T helper cell, helper cell, hematopoietic stem cell, human, human signal transducer and activator of transcription 1, immune-mediated cytopenias, immunodeficiency, mucocutaneous candidiasis, patient, patients, ruxolitinib, signal transducer and activator of transcription 1, type I and II interferons
Author NameAffiliation
Ashley S PlantBoston Children's Hospital, Harvard Medical School, Dana-Farber Cancer Institute
Clement MaBoston Children's Hospital, Harvard Medical School, Dana-Farber Cancer Institute
Sergio D RosenzweigPrimary Immunodeficiency Clinic, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Clinical Center
  • 1 - 3

Datasets

Release 1.2